Current Report Filing (8-k)
January 13 2020 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January
13, 2020
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware
|
|
001-37526
|
|
26-0389433
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrant’s Telephone Number, Including
Area Code)
Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
|
¨
|
Pre–commencement
communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
|
¨
|
Pre–commencement
communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
|
ZYNE
|
|
The NASDAQ Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. x
On January 13, 2020, Zynerba Pharmaceuticals,
Inc. (the “Company”) issued a press release announcing the achievement of its enrollment target for the Company’s
Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel
to Children and Adolescents with Autism Spectrum Disorder) trial of Zygel for the treatment of pediatric and adolescent
patients with autism spectrum disorder. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein
by reference.
On January 13, 2020 the Company also issued
a press release announcing that enrollment is nearing completion in the Company’s pivotal CONNECT-FX (Clinical study
of Cannabidiol (CBD) in Children and Adolescents with Fragile X) trial of Zygel
in children and adolescents with Fragile X syndrome and providing updates regarding its product pipeline. A copy of this press
release is attached hereto as Exhibit 99.2 and incorporated herein by reference.
On January 13, 2020, the Company posted
on its website a slide presentation, which is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated
herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and
other parties from time to time.
|
Item 9.01
|
Financial Statements and Exhibits
|
The following exhibits are being filed herewith:
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 13, 2020
|
ZYNERBA PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Suzanne Hanlon
|
|
|
Name: Suzanne Hanlon
|
|
|
Title: Secretary, Vice President and General Counsel
|
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2023 to Apr 2024